Tonix Pharmaceuticals’ (TNXP) “Outperform” Rating Reiterated at Noble Financial

Noble Financial reaffirmed their outperform rating on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report released on Thursday,Benzinga reports. They currently have a $70.00 price objective on the stock.

Separately, StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research note on Monday, February 10th. They issued a “sell” rating on the stock.

Tonix Pharmaceuticals Price Performance

Tonix Pharmaceuticals stock opened at $23.03 on Thursday. The company has a market capitalization of $43.04 million, a PE ratio of 0.00 and a beta of 2.23. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The stock has a 50-day moving average price of $18.44 and a two-hundred day moving average price of $19.76. Tonix Pharmaceuticals has a 12 month low of $6.76 and a 12 month high of $1,146.01.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($9.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.23) by ($3.54). Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.58 million during the quarter, compared to the consensus estimate of $3.20 million. Analysts expect that Tonix Pharmaceuticals will post -1762.5 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Commonwealth Equity Services LLC acquired a new position in Tonix Pharmaceuticals in the fourth quarter valued at $40,000. Two Sigma Investments LP bought a new stake in shares of Tonix Pharmaceuticals during the 4th quarter valued at about $66,000. PFG Investments LLC acquired a new stake in Tonix Pharmaceuticals during the fourth quarter worth approximately $72,000. Northern Trust Corp bought a new stake in Tonix Pharmaceuticals in the fourth quarter worth approximately $162,000. Finally, Point72 Asset Management L.P. bought a new position in shares of Tonix Pharmaceuticals during the 4th quarter worth approximately $526,000. Institutional investors and hedge funds own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.